{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.5","upperLimit":"53.1","value":"10.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"The time from the first dose date to the first observation of a disease progression or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with malignant PEComa were treated with 100 mg/m2 nab-sirolimus (30 mins IV infusion) on Days 1 and 8 in a 21-day cycle.","id":"OG000","title":"Experimental: Nab-Sirolimus"}],"paramType":"MEDIAN","populationDescription":"Efficacy Evaluable Patient Population","reportingStatus":"POSTED","timeFrame":"from start of treatment to first documented disease progression, through study completion (up to 72 months)","title":"Progression-free Survival (Median)","type":"SECONDARY","unitOfMeasure":"months"}